Physician profile
Jack M Matheny
NPI 1629040043
$9,875.57
in general payments reported to CMS, 2019-2025
46 companies · $34.23 in 2025
The $34.23 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,110 · 2020: $1,813 · 2021: $2,236 · 2022: $888 · 2023: $1,683 · 2024: $1,112 · 2025: $34.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,828.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,094.00 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $1,598.15 | 2019-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,403.32 | 2019-2024 | Lokelma, Breztri, Airsupra |
| Abbvie INC. | $837.51 | 2021-2024 | |
| Astellas Pharma US INC | $477.09 | 2019-2023 | Myrbetriq |
| Sunovion Pharmaceuticals INC. | $399.82 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $273.01 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $246.39 | 2019-2024 | |
| Glaxosmithkline, LLC. | $219.06 | 2019-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $204.75 | 2019-2024 | Verquvo, Dificid, Januvia |
| Radius Health, INC. | $165.24 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.66 | 2021-2024 | |
| Pfizer INC. | $141.95 | 2019-2023 | |
| Amarin Pharma, INC. | $125.07 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $119.73 | 2023-2024 | Quviviq |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Matheny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.